- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
P&G Health delivered strong FY26 results: sales neared ₹1400 Cr (+16% YoY) and PAT hit ₹327 Cr (+30% YoY). Over five years, sales grew high single-digits and profit expanded 13% annually, with ROE up 42%. Key brands like Neurobion and Livogen surged ~20%, while Nasivion and Evion saw high single-digit growth.
The company's "Integrated Growth Strategy," focused on product superiority, retail execution, and productivity, drove these results, including ₹35 Cr in savings this year. New launches like Livogen Iron Gummies (now #1 on Amazon) contributed early single-digit growth. Distribution reach significantly expanded, adding nearly 30,000 pharmacies/HCPs. Exports also saw encouraging growth.
Management is confident in sustaining balanced growth, leveraging increasing health awareness, the expanding VMS market, and a shift towards preventive healthcare. They view GLP-1 treatments as a complementary opportunity. The company projects a confident outlook, emphasizing strong brands, innovation, and expanded market reach.